2-amino-5-imidazol-1-yl-3-methylaniline | 131885-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-amino-5-imidazol-1-yl-3-methylaniline
• 英文别名: 5-imidazol-1-yl-3-methyl-benzene-1,2-diamine；5-imidazol-1-yl-3-methylbenzene-1,2-diamine
• CAS: 131885-95-5
• 化学式: C₁₀H₁₂N₄
• 分子量: 188.232
• InChiKey: JRHAXYKFTBEDMV-UHFFFAOYSA-N

物化性质

• 沸点：
  433.4±45.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  69.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-amino-5-imidazol-1-yl-3-methylaniline 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 生成 3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-4-iodo-1H-pyridin-2-one
  参考文献：
  名称：

  Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)

  摘要：

  The discovery and synthesis of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor I receptor (IGF-1R) are presented. Installing amine containing side chains at the 4-position of pyridone ring significantly improved the enzyme potency. SAR and biological activity of these compounds is presented. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.102
• 作为产物：
  描述：

  5-氟-2-硝基甲苯 在 palladium on activated charcoal 吡啶 、 4-二甲氨基吡啶 、 氢氧化钾 、 硫酸 、 氢气 、 硝酸 、 溶剂黄146 、 环己烯 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 生成 2-amino-5-imidazol-1-yl-3-methylaniline
  参考文献：
  名称：

  Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

  摘要：

  A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.041
• 作为试剂：
  描述：

  tert-butyl[(1S)-1-(3-bromobenzyl)-2-hydroxyethyl]carbamate 、 盐酸 在 2-amino-5-imidazol-1-yl-3-methylaniline 作用下， 以 甲醇 、 1,4-二氧六环 为溶剂， 反应 14.01h， 生成 (2S)-2-amino-3-(3-bromophenyl)propan-1-ol
  参考文献：
  名称：

  Benzimidazole C-2 heterocycles as kinase inhibitors

  摘要：

  提供具有一般式I的苯并咪唑衍生物。这些化合物可用作酪氨酸激酶抑制剂，特别是用于癌症治疗。

  公开号：

  US07312215B2

文献信息

• Novel tyrosine kinase inhibitors
  申请人：——

  公开号：US20040044203A1

  公开（公告）日：2004-03-04

  The present invention provides compounds of formula I 1 and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

  本发明提供了公式I1的化合物及其药用盐。公式I化合物抑制酪氨酸激酶酶，因此可用作抗癌剂。公式I化合物还可用于治疗其他可以通过抑制酪氨酸激酶酶来治疗的疾病。
• [EN] NOVEL TYROSINE KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA TYROSINE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002079192A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula I[ ] and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

  本发明提供了I[ ]式化合物及其药学上可接受的盐。I式化合物抑制酪氨酸激酶酶，因此可用作抗癌剂。I式化合物也可用于治疗其他可以通过抑制酪氨酸激酶酶来治疗的疾病。
• Tyrosine kinase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US07232826B2

  公开（公告）日：2007-06-19

  The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes

  本发明提供了公式I或II的化合物，其可用作抗癌剂和其他可以通过抑制酪氨酸激酶酶而治疗的疾病。
• Cardiotonic agents. Synthesis and cardiovascular properties of novel 2-arylbenzimidazoles and azabenzimidazoles
  作者：Timur Gungor、Andre Fouquet、Jean Marie Teulon、Daniel Provost、Michele Cazes、Alix Cloarec

  DOI：10.1021/jm00101a024

  日期：1992.11

  Novel 2-arylbenzimidazoles and azabenzimidazoles were synthesized, and their inotropic action was evaluated. Changes in left ventricular pressure, dP/dt max, were measured as an index of cardiac contractility. The structural features that impart optimal inotropic activity are presented. The most potent compounds were evaluated orally in conscious dogs with implanted Konigsberg pressure transducers. To investigate the mechanism of action, the most potent compounds were tested for their calcium-sensitizing properties and their potential for the inhibition of phosphodiesterase. Two compounds, 1 and 4 1, showed interesting in vitro and oral activity without side effects. They have a more potent calcium-sensitizing effect than MCI-154 and are under futher investigation.
• EP1381598A4
  申请人：——

  公开号：EP1381598A4

  公开（公告）日：2008-03-19